Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease.

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease.
复制标题

有和没有帕金森病的葡萄糖脑苷脂酶携带者中的细胞因子和戈谢生物标志物。

DOI:
10.1002/mds.28525
复制
发表时间:
2021-06
期刊:
Movement disorders : official journal of the Movement Disorder Society
影响因子:
--
通讯作者:
Alcalay RN
Alcalay RN
中科院分区:
其他
文献类型:
--
作者:
Galper J;Balwani M;Fahn S;Waters C;Krohn L;Gan-Or Z;Dzamko N;Alcalay RN

文献摘要

参考文献

被引文献

相似文献

葡萄糖脑苷酶(GBA)的纯合子和复合杂合子变异可引起戈谢病(GD),而杂合子变异可增加患帕金森病(PD)的风险。GD患者显示外周免疫蛋白改变。然而,尚不清楚这些在GBA携带者PD中是否会改变。确定与GD相关的血浆细胞因子和免疫生物标志物在伴有或不伴有PD的GBA携带者中是否也发生改变。在患有(n = 135)和未患有(n = 83) PD的GBA致病变异携带者以及患有(n = 75)和未患有PD的非携带者(n = 77)中测量炎症因子和已建立的GD生物标志物,铁蛋白,CD162, CCL18和壳三酸苷酶(28个生物标志物)。具有GBA双等位基因致病变异的PD患者血浆铁蛋白、CCL18和MIP1α水平升高。这些生物标志物在杂合型GBA携带者中没有升高。GD血浆生物标志物对于区分杂合子GBA致病变异携带者患PD的风险并不是很有希望的候选者。©2021作者。Wiley期刊有限责任公司代表国际帕金森和运动障碍学会出版的《运动障碍》
Homozygous and compound heterozygous variants in glucocerebrosidase (GBA) can cause Gaucher disease (GD), whereas heterozygous variants increase the risk of developing Parkinson's disease (PD). GD patients display altered peripheral immune proteins. However, it is unknown if these are altered in GBA carriers with PD. To determine whether plasma cytokines and immune biomarkers associated with GD are also altered in GBA carriers with or without PD. Inflammatory cytokines and established GD biomarkers, ferritin, CD162, CCL18, and chitotriosidase (28 biomarkers) were measured in GBA pathogenic variant carriers with (n = 135) and without (n = 83) PD, and non‐carriers with (n = 75) and without PD (n = 77). PD patients with biallelic pathogenic variants in GBA had elevated plasma levels of ferritin, CCL18, and MIP1α. These biomarkers were not elevated in heterozygous GBA carriers. GD plasma biomarkers are not promising candidates for stratifying the risk for PD in carriers of heterozygous GBA pathogenic variants. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
DOI: 10.1007/s40263-020-00746-0
发表时间: 2020-07-01
期刊: CNS DRUGS
影响因子: 6
作者:
Menozzi, Elisa;Schapira, Anthony H., V
通讯作者: Schapira, Anthony H., V
DOI: 10.1007/s10545-018-0142-y
发表时间: 2018-09
影响因子: 4.2
作者:
Regenboog M;van Dussen L;Verheij J;Weinreb NJ;Santosa D;Vom Dahl S;Häussinger D;Müller MN;Canbay A;Rigoldi M;Piperno A;Dinur T;Zimran A;Mistry PK;Salah KY;Belmatoug N;Kuter DJ;Hollak CEM
通讯作者: Hollak CEM
DOI: 10.4061/2011/436813
发表时间: 2011-02-22
期刊: Parkinson's disease
影响因子: --
作者:
Ferrari CC;Tarelli R
通讯作者: Tarelli R
DOI: 10.1212/wnl.0b013e318245f476
发表时间: 2012-02-01
期刊: NEUROLOGY
影响因子: 9.9
作者:
Anheim, M.;Elbaz, A.;Brice, A.
通讯作者: Brice, A.
DOI: 10.1038/s41531-019-0086-4
发表时间: 2019-07-25
影响因子: 8.7
作者:
Rastegar, Diba Ahmadi;Ho, Nicholas;Dzamko, Nicolas
通讯作者: Dzamko, Nicolas